School of Chemical Science and Technology, Yunnan University, Kunming, People's Republic of China.
Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, People's Republic of China.
Int J Nanomedicine. 2023 Jan 13;18:225-241. doi: 10.2147/IJN.S386253. eCollection 2023.
Gallium (III) metal-organic complexes have been shown to have the ability to inhibit tumor growth, but the poor water solubility of many of the complexes precludes further application. The use of materials with high biocompatibility as drug delivery carriers for metal-organic complexes to enhance the bioavailability of the drug is a feasible approach.
Here, we modified the ligands of gallium 8-hydroxyquinolinate complex with good clinical anticancer activity by replacing the 8-hydroxyquinoline ligands with 5-bromo-8-hydroxyquinoline (HBrQ), and the resulting Ga(III) + HBrQ complex had poor water solubility. Two biocompatible materials, bovine serum albumin (BSA) and graphene oxide (GO), were used to synthesize the corresponding Ga(III) + HBrQ complex nanoparticles (NPs) BSA/Ga/HBrQ NPs and GO/Ga/HBrQ NPs in different ways to enhance the drug delivery of the metal complex.
Both of BSA/Ga/HBrQ NPs and GO/Ga/HBrQ NPs can maintain stable existence in different solution states. In vitro cytotoxicity test showed that two nanomedicines had excellent anti-proliferation effect on HCT116 cells, which shown higher level of intracellular ROS and apoptosis ratio than that of cisplatin and oxaliplatin. In addition, the superior emissive properties of BSA/Ga/HBrQ NPs and GO/Ga/HBrQ NPs allow their use for in vivo imaging showing highly effective therapy in HCT116 tumor-bearing mouse models.
The use of biocompatible materials for the preparation of NPs against poorly biocompatible metal-organic complexes to construct drug delivery systems is a promising strategy that can further improve drug delivery and therapeutic efficacy.
镓(III)金属有机配合物已被证明具有抑制肿瘤生长的能力,但许多配合物的水溶性差,限制了其进一步的应用。利用具有高生物相容性的材料作为金属有机配合物的药物载体来提高药物的生物利用度是一种可行的方法。
在这里,我们通过用 5-溴-8-羟基喹啉(HBrQ)代替 8-羟基喹啉配体来修饰具有良好临床抗癌活性的镓 8-羟基喹啉配合物的配体,得到的 Ga(III) + HBrQ 配合物水溶性差。我们使用两种生物相容性材料,牛血清白蛋白(BSA)和氧化石墨烯(GO),以不同的方式合成相应的 Ga(III) + HBrQ 配合物纳米颗粒(NPs)BSA/Ga/HBrQ NPs 和 GO/Ga/HBrQ NPs,以增强金属配合物的药物传递。
BSA/Ga/HBrQ NPs 和 GO/Ga/HBrQ NPs 都可以在不同的溶液状态下保持稳定的存在。体外细胞毒性试验表明,两种纳米药物对 HCT116 细胞具有优异的抗增殖作用,其细胞内 ROS 和细胞凋亡率均高于顺铂和奥沙利铂。此外,BSA/Ga/HBrQ NPs 和 GO/Ga/HBrQ NPs 的优异发光性能使其可用于体内成像,在 HCT116 荷瘤小鼠模型中显示出高效的治疗效果。
使用生物相容性材料制备对生物相容性差的金属有机配合物的 NPs 构建药物传递系统是一种很有前途的策略,可以进一步提高药物传递和治疗效果。